Check how courts have cited this case. Use our free citator for the most current treatment.
No. 10369109
United States Court of Appeals for the Ninth Circuit
Sohovich v. Avalara, Inc.
No. 10369109 · Decided March 31, 2025
No. 10369109·Ninth Circuit · 2025·
FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
March 31, 2025
Citation
No. 10369109
Disposition
See opinion text.
Full Opinion
NOT FOR PUBLICATION FILED
UNITED STATES COURT OF APPEALS MAR 31 2025
MOLLY C. DWYER, CLERK
U.S. COURT OF APPEALS
FOR THE NINTH CIRCUIT
MARTIN SOHOVICH, On behalf of No. 24-1646
himself and all others similarly situated, D.C. No.
2:22-cv-01580-MJP
Plaintiff - Appellant,
v. MEMORANDUM*
AVALARA, INC.; SCOTT
MCFARLANE; BRUCE
CRAWFORD; MARION
FOOTE; EDWARD GILHULY; WILLIAM
INGRAM; MARCELA MARTIN; TAMI
RELLER; BRIAN SHARPLES; RAJEEV
SINGH; SRINIVAS
TALLAPRAGADA; KATHY ZWICKERT,
Defendants - Appellees.
Appeal from the United States District Court
for the Western District of Washington
Marsha J. Pechman, District Judge, Presiding
Argued and Submitted March 4, 2025
San Francisco, California
Before: GOULD and NGUYEN, Circuit Judges, and BENNETT, District Judge.**
*
This disposition is not appropriate for publication and is not precedent
except as provided by Ninth Circuit Rule 36-3.
**
The Honorable Richard D. Bennett, United States District Judge for
the District of Maryland, sitting by designation.
Martin Sohovich filed a class action suit against Avalara Inc. and its Board
of Directors (collectively, “Avalara”) alleging violations of Sections 14(a) and
20(a) of the Securities Exchange Act of 1934 and SEC Rule l 4a-9. He alleges that
Avalara misrepresented the fairness of the company’s $8.4 billion sale to Vista
Equity Partners Management, LLC through false and misleading Proxy statements
and financial projections. The district court dismissed the case with prejudice
based on Sohovich’s failure to adequately plead the objective falsity or misleading
nature of any of the Proxy statements or Projections. Sohovich timely appealed.
We have jurisdiction under 28 U.S.C. § 1291. Our review is de novo and
“we accept all factual allegations as true and view them in the light most favorable
to Plaintiffs. In addition to the factual allegations in the complaint, we may
consider any materials incorporated into the complaint by reference.” Glazer
Capital Mgmt., L.P. v. Forescout Techs., Inc., 63 F.4th 747, 763 (9th Cir. 2023).1
To survive dismissal, a plaintiff must allege “enough facts to state a claim to relief
that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570
(2007). In addition, the Private Securities Litigation Reform Act or the “PSLRA
imposes formidable pleading requirements to properly state a claim and avoid
dismissal under Rule 12(b)(6).” Glazer, 63 F.4th at 765 (cleaned up). “To plead
1
Avalara’s unopposed motion to supplement or correct the record with the full
copy of its “Analyst Day” presentation is granted. See Knievel v. ESPN, 393 F.3d
1068, 1076 (9th Cir. 2005) (explaining the incorporation by reference doctrine).
2 24-1646
falsity adequately under the PSLRA, the complaint shall specify each statement
alleged to have been misleading, the reason or reasons why the statement is
misleading, and, if an allegation regarding the statement or omission is made on
information and belief, the complaint shall state with particularity all facts on
which that belief is formed.” Id. (citing 15 U.S.C. § 78u-4(b)(1)). “In doing so,
the plaintiff must ‘reveal the sources of his information.’” Id. (cleaned up). But “a
defendant will not be liable for a false or misleading statement if it is forward-
looking and either is accompanied by cautionary language or is made without
actual knowledge that it is false or misleading” under the PSLRA’s safe harbor
provision. Id. at 767 (cleaned up); 15 U.S.C. § 78u-5(i)(1)(B). Also inactionable
is puffery or subjective, “vague statements of optimism” about a company’s value
or performance. See In re Cutera Sec. Litig., 610 F.3d 1103, 1111 (9th Cir. 2010).
Applying these principles, we affirm in part, reverse and vacate in part, and
remand.
1. At the outset, the PSLRA’s safe harbor does not apply here. The Proxy’s
statements that the projections were “prepared on a reasonable basis” or “reflected
the best currently available estimates and judgments” are “not forward-looking.”
See In re Quality Sys., Inc. Sec. Litig., 865 F.3d 1130, 1141 (9th Cir. 2017). They
are instead statements about the preparation of, and basis for, the projections that
incorporated then-existing, verifiable facts. The district court’s meticulous
3 24-1646
analysis of the issue was therefore correct.2
2. The Proxy’s statements about Avalara’s challenges with new and upsell
bookings are not objectively false or misleading. Avalara never stated that it did
not need new bookings, and Avalara’s purportedly contradictory statements
indicating it was “doing well” are puffery. See In re Cutera, 610 F.3d at 1111
(“[I]nvestors do not rely on vague statements … like ‘good,’ ‘well-regarded,’ or
other feel good monikers”). The “numerically specific” figures Sohovich says
Avalara emphasized do not render the puffery actionable. Avalara did not tout
25% growth in Q1 2022 upsell bookings “to claim that the company would not
need any new bookings,” and the Analyst Day materials citing the 25% figure
reveals that 25% is in fact lower than the upsell growth rate of 35% in 2020 and
44% in 2021. The 116% net retention rate, meanwhile, refers to cross-sell, not
upsell. The district court thus properly rejected this claim.
3. The district court also properly dismissed Sohovich’s claims regarding
the Proxy’s statement on Q2 2022 results being “below management expectations.”
Determining whether a claim survives requires the court to consider context and
apply “judicial experience and common sense.” See Ashcroft v. Iqbal, 556 U.S.
662, 679 (2009). The district court’s observation that “public guidance differs
from management’s own expectations,” especially given that Q2 2022 was the first
2
The parties’ dispute about whether the issue was preserved is thus immaterial.
4 24-1646
relevant quarter where Avalara failed to beat analysts’ revenue expectations, was
therefore not an “improper inference” or error.
4. The district court correctly found that the Proxy’s statements about the
impact of lost business from Partner A and other international risks were not
objectively false or misleading. Aside from being puffery, Avalara’s minimization
of the impact of any potential loss of business from Partner A does not mean that
the loss would have no impact on the company. Nor does the prospect of other
international business make the projections false or misleading in light of
Avalara’s continued emphasis on other challenges in the area.
5. The district court also correctly found that the Proxy’s statements about
macroeconomic and compliance risks were not false or misleading. Avalara’s
rhetoric about its “resilience” and “insulation from macroeconomic risk” is
puffery. See Glen Holly Entm’t, Inc. v. Tektronix Inc., 352 F.3d 367, 379 (9th Cir.
2003). Meanwhile, CEO Scott McFarlane’s statement that by 2025, “80% of
organizations will be forced” to use programs like Avalara is also “the kind of
booster confidence any reasonable investor would expect from a CEO.” In re
CornerStone Propane Partners, L.P. Sec. Litig., 355 F. Supp. 2d 1069, 1087 (N.D.
Cal. 2005). It is also too generalized and incapable of objective verification to be
false or misleading when it was made. Cf. In re Facebook, Inc., 87 F.4th 934,
948–49 (9th Cir. 2023) (finding statement that risks could materialize plausibly
5 24-1646
false where “in fact, those risks had already materialized”). The district court
therefore properly rejected these claims.
6. But the district court erred in holding that Avalara’s statements about the
Institutional Shareholder Services’ (ISS) view of the sale was not objectively false
or misleading. Sohovich alleges that Avalara quoted ISS’s report without
permission and that the report stated “‘the merger consideration is a substantial
discount to ALVR historic trading levels;’” that Altair’s “‘scathing criticism of the
merger’” was “‘credible;’” that Avalara “‘has a strong market position focused on
one of the two certainties in life, taxes,’” and it “‘remains viable in the medium to
long term with sufficient cash balances and cash flow to achieve management’s
operational objectives;’” that “ISS also found that ‘[t]he shift in narrative from
[Avalara’s] management is concerning, with a whiplash turn from positive
comments … to current worries about employee attrition, European growth,
product development, and squandered opportunities;’” and that ISS explicitly
recommended a vote against certain parts of the deal, including the “golden
parachute” proposal for the CEO, which had no “compelling rationale.” These
particularized allegations, credited as true, “‘create an impression of a state of
affairs that differs in a material way from the one that actually exists,’” i.e., that
ISS’s recommendation was not as approbatory as Avalara touted. See In re
Facebook, Inc., 87 F.4th at 948. Indeed, it was “cautionary.”
6 24-1646
That some of the report’s unfavorable excerpts were filed by a third-party, in
a separate SEC filing, does not render Avalara’s statements about the report not
false or misleading. See Miller v. Thane Int’l, Inc., 519 F.3d 879, 881 (9th Cir.
2008) (“Investors are not generally required to look beyond a given document to
discover what is true and what is not. Ordinarily, omissions by corporate insiders
are not rendered immaterial by the fact that the omitted facts are otherwise
available to the public.” (cleaned up)). And while Avalara is correct that the ISS
ultimately issued a recommendation for the sale, “statements literally true on their
face may nonetheless be misleading when considered in context.” Id. at 886. “For
that reason, the disclosure required” by law “is measured not by literal truth, but by
the ability of the material to accurately inform rather than mislead.” In re
Convergent Tech. Sec. Litig., 948 F.2d 507, 512 (9th Cir. 1991).
7. The district court similarly erred in holding that the omission of inorganic
growth from the May and July Projections was not objectively false or misleading.
The omission is misleading, according to Sohovich, because “acquisitions have
always been a material part of Avalara’s growth story and management made clear
that they would continue to be a part of the Company’s DNA going forward.” He
cites a host of specific statements by Avalara’s management from earnings calls,
the Analyst Day presentation, and a press release as support. He underscores how
Avalara had always included inorganic growth in its guidance, and when it did not,
7 24-1646
it “explicitly stated as such,” like when CFO Tennenbaum did so on Analyst Day.
Sohovich also buttresses these claims with uncontested allegations that Avalara
acquired “twenty-eight companies from 2007 to 2021, including twelve between
2018 to 2021.” “Requiring more detail than those presently alleged would
transform the PSLRA’s formidable pleading requirement into an impossible one.”
Glazer, 63 F.4th at 769. Sohovich’s plethora of particularized allegations plausibly
suggests that the omission—and the lack of notice about such omission—could
materially mislead a reasonable investor.
Avalara’s counterarguments are unavailing. That it may not have an
obligation to include inorganic growth in projections or that doing so could be too
speculative and therefore potentially unlawful misses the point. Avalara has not
cited specific acquisitions as a source of growth in its previous guidance, and the
PSLRA’s safe harbor protects Avalara’s forward-looking statements so long as it is
“accompanied by cautionary language or is made without actual knowledge that it
is false or misleading.” Glazer, 63 F.4th at 767 (cleaned up). And the fact that
Avalara lost a potential acquisition during the sales process does not mean it
planned to cease pursuing inorganic growth. As Sohovich points out, Avalara
indicated quite the opposite in its communications, including right after the sale.
Sohovich thus adequately pled the objective falsity or misleading nature of the
8 24-1646
omission of inorganic growth from the projections.3
8. As just discussed, Sohovich has adequately pled the objective falsity of
the Proxy’s statements about the ISS report and the omission of inorganic growth
from the projections. He may therefore have a viable Section 14(a) and Rule 14a-9
claim, which, in turn, suggests the viability of a section 20(a) claim. See Glazer,
63 F.4th at 765 (noting that section 20(a) liability is derivative of other Exchange
Act violations). It was thus error for the district court to dismiss Sohovich’s
section 20(a) claim.
9. The district court properly dismissed Sohovich’s claims about the Proxy
supplement. Sohovich neither specifies, as in the district court, which Proxy
statements were “regurgitate[d]” nor explains, with sufficient particularly, the
reasons why the statements are misleading. See 15 U.S.C. § 78u-4(b)(1)(B).
3
Avalara’s attempt to distinguish NECA-IBEW Pension Tr. Fund (The Decatur
Plan) v. Precision Castparts Corp., which found the omission of inorganic growth
in projections materially misleading, is also unpersuasive. Fed. Sec. L. Rep. ¶
99,901 (D. Or. Oct. 3, 2017). That defendant Precision in The Decatur Plan,
unlike Avalara, “focuse[d] on M&A first” and foremost does not defeat Sohovich’s
allegations at this stage. All well-pled “allegations of material fact must be taken
as true and construed in the light most favorable to the non-moving party.” Glazer,
63 F.4th at 763. Sohovich has alleged, repeatedly and with particularity, that
M&A has always been a part of Avalara’s “DNA,” much like Precision, which also
engaged in significant M&A activity and likewise stated that M&A was in its
“DNA.” See Fed. Sec. L. Rep. ¶ 99,901. Notable, too, is Precision’s disclosure of
its omission of M&A in its forecasts—something Avalara did not do here. As
Sohovich argues, it potentially makes Avalara’s omission more misleading given
the allegations of Avalara’s history of including inorganic growth in its forecasts.
9 24-1646
***
In sum, we REVERSE the district court’s holding that Sohovich did not
adequately plead the objective falsity or misleading nature of Avalara’s statements
about ISS’s recommendation of the sale and the omission of inorganic growth from
the Projections. We also VACATE the district court’s dismissal of Sohovich’s
section 20(a) claim. Because it declined to reach the other elements of Sohovich’s
Section 14(a) and Rule 14a-9 claim, the district court, on REMAND, should
address, as to Avalara’s statement about ISS’s report and the Projections’ omission
of inorganic growth: (1) subjective falsity and negligence, except for CEO
McFarlane; (2) materiality, to the extent the district court found them immaterial;
and (3) loss causation. Afterward, the district court should consider whether
Sohovich’s claim amounts to a viable section 14(a) or Rule 14a-9 violation so as to
trigger section 20(a) liability. We otherwise AFFIRM.
Each party shall bear its own costs.
10 24-1646
Plain English Summary
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS MAR 31 2025 MOLLY C.
Key Points
01NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS MAR 31 2025 MOLLY C.
02COURT OF APPEALS FOR THE NINTH CIRCUIT MARTIN SOHOVICH, On behalf of No.
03MEMORANDUM* AVALARA, INC.; SCOTT MCFARLANE; BRUCE CRAWFORD; MARION FOOTE; EDWARD GILHULY; WILLIAM INGRAM; MARCELA MARTIN; TAMI RELLER; BRIAN SHARPLES; RAJEEV SINGH; SRINIVAS TALLAPRAGADA; KATHY ZWICKERT, Defendants - Appellees.
04Pechman, District Judge, Presiding Argued and Submitted March 4, 2025 San Francisco, California Before: GOULD and NGUYEN, Circuit Judges, and BENNETT, District Judge.** * This disposition is not appropriate for publication and is not preced
Frequently Asked Questions
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS MAR 31 2025 MOLLY C.
FlawCheck shows no negative treatment for Sohovich v. Avalara, Inc. in the current circuit citation data.
This case was decided on March 31, 2025.
Use the citation No. 10369109 and verify it against the official reporter before filing.